Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
Christelle Orlando, Coagulation Lab Expert at UZ Brussel and Vrije University Brussel, has shared a post on LinkedIn:
“New publication alert
I’m proud to present our recent paper on diagnosis on inherited antithrombin deficiency, published in Thrombosis and Haemostasis.
Diagnostic performance of commercial antithrombin activity assays: do we get what we expect?
In this paper, we compared the most commonly used antithrombin (AT) activity assays in their ability to diagnose inherited antithrombin deficiency, with a focus on type II AT deficiencies.
Key findings:
- Sensitive commercial AT activity assays are mandatory to identify AT deficiency
- Diagnostic sensitivity of commercial AT assays varies widely
- Some commercial AT activity assays are not suited for diagnosis of AT deficiency
- We report the first method comparison data from AT activity assays performed on CN6000 and sthemO301
- We describe two novel SERPINC1 variants responsible for type II AT deficiency
Take home messages:
This study highlights the poor performance of commercial antithrombin activity assays in their ability to detect type II AT deficiency. Our results suggest that this subtype of AT deficiency, a severe thrombotic disorder, is underdiagnosed.”
Title: Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?
Authors: Christelle Orlando, Céline Drèze, Anton Evenepoel, Sara Seneca, Kristin Jochmans

Read the full paper here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM